Belantamab mafodotin-blmf
Belantamab mafodotin-blmf Uses, Dosage, Side Effects, Food Interaction and all others data.
Belantamab mafodotin-blmf, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF).
Belantamab mafodotin-blmf was granted FDA approval on 5 August 2020.
Belantamab mafodotin-blmf treats multiple myeloma through antibody dependant cell mediated cytotoxicity as well as G2/M cell cycle arrest. It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks. Patients should be counselled regarding the risk of keratopathy.
| Trade Name | Belantamab mafodotin-blmf |
| Generic | Belantamab mafodotin |
| Belantamab mafodotin Other Names | Belantamab mafodotin, Belantamab Mafodotin-blmf |
| Type | Intravenous |
| Protein binding | Monoclonal antibodies are generally not protein bound. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Belantamab mafodotin-blmf is an anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
Belantamab mafodotin-blmf is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Belantamab mafodotin-blmf is also used to associated treatment for these conditions: Relapsed Or Refractory Multiple Myeloma
How Belantamab mafodotin-blmf works
Belantamab mafodotin-blmf, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF). Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody dependant cell mediated cytoxicity.
BCMA is uniquely expressed on CD138-positive myeloma cells. Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells. Belantamab mafodotin-blmf binds to BCMA, is internalised into cells, and releases MMAF.
The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.
Toxicity
Data regarding overdose is not readily available. However, keratopathy was seen in 71% of patients.
Food Interaction
No interactions found.Volume of Distribution
The mean steady state volume of distribution of belantamab mafodotin was 11 L.
Elimination Route
Belantamab mafodotin-blmf at a dose of 2.5mg/kg reaches a Cmax of 42 µg/mL, with a Tmax of 0.78 hours, and an AUC of 4666 µg*h/mL.
Half Life
The terminal half life of belantamab mafodotin was 12 days after the first dose and 14 days at steady state.
Clearance
The clearance of belantamab mafodotin was 0.9 L/day after the first dose and 0.7 L/day at steady state.
Elimination Route
Monoclonal antibodies are eventually phagocytosed and broken down to smaller peptides and amino acids which are eliminated in a similar fashion to other proteins. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.
Innovators Monograph
You find simplified version here Belantamab mafodotin-blmf
